Sionna Therapeutics (NASDAQ:SION) Director Ra Capital Management, L.P. Sells 6,922 Shares of Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Ra Capital Management, L.P. sold 6,922 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $39.57, for a total value of $273,903.54. Following the sale, the director directly owned 182,527 shares in the company, valued at $7,222,593.39. This trade represents a 3.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, November 19th, Ra Capital Management, L.P. sold 47,442 shares of Sionna Therapeutics stock. The stock was sold at an average price of $40.01, for a total value of $1,898,154.42.
• On Monday, November 17th, Ra Capital Management, L.P. sold 81,987 shares of Sionna Therapeutics stock. The stock was sold at an average price of $40.59, for a total value of $3,327,852.33.
• On Tuesday, October 28th, Ra Capital Management, L.P. sold 62,610 shares of Sionna Therapeutics stock. The shares were sold at an average price of $39.58, for a total value of $2,478,103.80.
• On Friday, October 24th, Ra Capital Management, L.P. sold 311,000 shares of Sionna Therapeutics stock. The stock was sold at an average price of $39.50, for a total value of $12,284,500.00.

Sionna Therapeutics Stock Down 1.8%

Shares of Sionna Therapeutics stock traded down $0.71 on Wednesday, hitting $38.41. The company’s stock had a trading volume of 255,628 shares, compared to its average volume of 239,955. The company has a market capitalization of $1.71 billion and a P/E ratio of -7.89. Sionna Therapeutics, Inc. has a 52-week low of $7.26 and a 52-week high of $43.19. The firm has a fifty day moving average price of $32.03 and a 200-day moving average price of $22.90.

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.06.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of SION. Russell Investments Group Ltd. acquired a new stake in shares of Sionna Therapeutics in the third quarter worth approximately $30,000. BNP Paribas Financial Markets acquired a new position in Sionna Therapeutics during the second quarter worth approximately $31,000. Police & Firemen s Retirement System of New Jersey purchased a new position in Sionna Therapeutics during the second quarter worth approximately $45,000. Virtus Investment Advisers LLC acquired a new position in shares of Sionna Therapeutics in the 2nd quarter valued at $96,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Sionna Therapeutics in the 2nd quarter valued at $117,000.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on SION shares. Jones Trading assumed coverage on Sionna Therapeutics in a research report on Monday, September 8th. They set a “buy” rating and a $46.00 price objective for the company. Raymond James Financial reiterated a “strong-buy” rating on shares of Sionna Therapeutics in a report on Wednesday, November 5th. BTIG Research began coverage on shares of Sionna Therapeutics in a research report on Wednesday. They issued a “buy” rating and a $50.00 price objective for the company. Royal Bank Of Canada began coverage on shares of Sionna Therapeutics in a research report on Wednesday, September 3rd. They set a “sector perform” rating and a $22.00 target price on the stock. Finally, Wall Street Zen cut shares of Sionna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $40.00.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.